Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | DPP4 | P27487 | 2/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.53 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.43 |
| ▸ | BMP1 | P13497 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31015849 | 1.00 | KMT2A (0.55) | KMT2AALOX15BLMPMP22DPP4 | |
| SCHEMBL31378337 | 1.00 | KMT2A (0.55) | KMT2AALOX15BLMPMP22DPP4 | |
| SCHEMBL29630337 | 1.00 | KMT2A (0.55) | KMT2AALOX15BLMPMP22DPP4 | |
| SCHEMBL5970495 | 0.96 | KMT2A (0.59) | KMT2AALOX15BLMPMP22DPP4 | |
| SCHEMBL31378335 | 0.96 | KMT2A (0.59) | KMT2AALOX15BLMPMP22DPP4 | |
| SCHEMBL19375 | 0.96 | KMT2A (0.59) | KMT2AALOX15BLMPMP22DPP4 | |
| SCHEMBL30288867 | 0.95 | FOLH1 (0.51) | KMT2AALOX15BLMPMP22DPP4 | |
| SCHEMBL29706692 | 0.95 | FOLH1 (0.51) | KMT2AALOX15BLMPMP22DPP4 | |
| SCHEMBL29636521 | 0.95 | FOLH1 (0.51) | KMT2AALOX15BLMPMP22DPP4 | |
| SCHEMBL30596280 | 0.95 | FOLH1 (0.51) | KMT2AALOX15BLMPMP22DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-20250345411-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-12390520-B2 | Vaccination in newborns and infants | Cure Vac SE (DE) | 2025-08-19 | — | — | US | disclosed |
| US-12391733-B2 | Stapled intracellular-targeting antimicrobial peptides to treat infection | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| WO-2025065355-A1 | POLYPEPTIDE PROBE AND KIT FOR EARLY DIAGNOSIS OF HUNTINGTON'S DISEASE | 京东方科技集团股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-20240390478-A1 | VACCINATION IN ELDERLY PATIENTS | CureVac SE (DE) | 2024-11-28 | — | — | US | disclosed |
| US-20240343765-A1 | STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION | DANA-FARBER CANCER INSTITUTE, INC. | 2024-10-17 | — | — | US | disclosed |
| US-12036277-B2 | Vaccination with mRNA-coded antigens | CureVac SE (DE) | 2024-07-16 | — | — | US | disclosed |
| US-20240197857-A1 | VACCINATION WITH mRNA-CODED ANTIGENS | CureVac SE (DE) | 2024-06-20 | — | — | US | disclosed |
| US-11975064-B2 | Vaccination with mRNA-coded antigens | CureVac SE (DE) | 2024-05-07 | — | — | US | disclosed |
| US-20230106577-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-3317294-B1 | STABILIZED ANTI-MICROBIAL PEPTIDES | DANA FARBER CANCER INST INC (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-3344275-B1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS INC (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11478552-B2 | Hybrid carriers for nucleic acid cargo | CUREVAC AG (DE) | 2022-10-25 | — | — | US | disclosed |
| WO-2022170108-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF IN PREVENTION OF RADIATION INJURY | AILERON THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| CN-114853866-A | Peptidomimetic macrocycles | 艾瑞朗医疗公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-112500466-B | Peptidomimetic macrocycles | 艾瑞朗医疗公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-108348571-B | Peptidomimetic macrocycles and uses thereof | 艾瑞朗医疗公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114173878-A | Peptidomimetic macrocycles and uses thereof | 艾瑞朗医疗公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478552-B2 | Hybrid carriers for nucleic acid cargo | HNRNPH1, HNRNPH3, SNRPE | KMT2A 3349/4885ALOX15 2734/4885BLM 967/4885 |
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | HLA-DRB1, TLR3, TLR9 | KMT2A 1880/4885ALOX15 3236/4885BLM 1885/4885 |
| US-20240343765-A1 | STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION | VIP, SPPL2B, HM13 | KMT2A 4793/4885ALOX15 3355/4885BLM 3040/4885 |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | BID, FLT3, GRPR | KMT2A 3413/4885ALOX15 4124/4885BLM 362/4885 |
| US-20230106577-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | TP53, TP53BP1, MDM2 | KMT2A 3448/4885ALOX15 4685/4885BLM 440/4885 |
| US-12391733-B2 | Stapled intracellular-targeting antimicrobial peptides to treat infection | VIP, SPPL2B, HM13 | KMT2A 4793/4885ALOX15 3355/4885BLM 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.